Therefore, this meta-analysis included all available randomized controlled trials (RCTs) aimed at exploring the efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in the adjuvant or neoadjuvant treatment of patients with HR-positive/HER2-negative early breast cancer. The gene discussed is CDK4; the disease is breast carcinoma.